ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Sanofi Sells Dermik Unit To Valeant For $425 Million

PARIS -(Dow Jones)- French pharmaceutical giant Sanofi SA (SAN.FR) said Monday it sold Dermik, its dermatology unit, to Canada-based Valeant Pharmaceuticals International Inc. (VRX) for $425 million in cash. The transaction involves Dermik assets, comprising an aesthetic and therapeutic dermatology business in the U.S. and Canada and an aesthetic dermatology business in other parts of the world, which had sales of $206 million in 2010, Sanofi said. Dermik has a significant presence in the medical dermatology market in the U.S. and Canada, with a strong field force and well-known brands, which include BenzaClin, Carac and Sculptra. Sanofi decided to sell Dermik to focus on its "growth platforms" and "innovation." The French company recently bought U.S. biotech firm Genzyme for $20 billion and a string of smaller firms prior to the Genzyme takeover. The transaction will still have to be cleared by certain antitrust authorities and meet other customary conditions. -By Inti Landauro, Dow Jones Newswires; +33 1 4017 1740; inti.landauro@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
07/28/201601:00:00Pharming Reports on Financial Results for the First Six Months...
07/26/201608:30:00Progenics Receives $50 Million Milestone Payment Following FDA...
07/22/201617:00:00Toronto Stocks Rise as Earnings Offset Falling Oil and Gold Prices
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/19/201621:40:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201621:02:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201619:19:00Valeant, Progenics Shares Rise on Constipation Drug Approval
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201617:48:00Valeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/18/201601:00:00Pharming Announces Positive Results from Randomized Controlled...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/14/201609:43:00Valeant's Ex-CEO Michael Pearson Sells Nearly $100 Million in...
07/14/201608:50:00Valeant Pharmaceuticals Comments On Recent Stock Transactions
07/14/201608:50:00Valeant Pharmaceuticals Comments On Recent Stock Transactions
07/14/201603:04:00Pearson Sells Large Valeant Stake -- WSJ

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad